Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.3910
+0.0150 (3.99%)
At close: May 22, 2026, 4:00 PM EDT
0.3920
+0.0010 (0.26%)
After-hours: May 22, 2026, 7:32 PM EDT
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $72.10K. In the year 2025, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
88.21
Revenue / Employee
$24,034
Employees
3
Market Cap
6.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.10K | - | - |
| Dec 31, 2024 | 72.10K | - | - |
| Dec 31, 2023 | 72.10K | - | - |
| Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
| Dec 31, 2021 | 71.26K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.19M |
| CollPlant Biotechnologies | 2.37M |
| BioAtla | 2.00M |
| XTL Biopharmaceuticals | 968.00K |
| Addex Therapeutics | 218.17K |
| Alaunos Therapeutics | 3.00K |
SILO News
- 17 days ago - Silo Pharma files provisional patent for ibogaine-based therapeutics - TheFly
- 18 days ago - Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury - GlobeNewsWire
- 26 days ago - Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD - GlobeNewsWire
- 4 weeks ago - Silo Pharma expands into AI technology with Qwikagents asset purchase - TheFly
- 4 weeks ago - Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents - GlobeNewsWire
- 6 weeks ago - Silo Pharma gets European Patent Office allowance for PTSD prevention therapy - TheFly
- 6 weeks ago - Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - GlobeNewsWire
- 3 months ago - Silo Pharma announces $1M share repurchase program - TheFly